These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 27478536)

  • 21. Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure.
    Yoo J; Hann HW; Coben R; Conn M; DiMarino AJ
    Diseases; 2018 Apr; 6(2):. PubMed ID: 29677098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of Related Factors for Persistent Risk of Hepatitis B Virus-Associated Hepatocellular Carcinoma.
    Varghese N; Majeed A; Nyalakonda S; Boortalary T; Halegoua-DeMarzio D; Hann HW
    Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New paradigms in hepatitis B management: only diamonds are forever.
    Coffin CS; Lee SS
    Br Med Bull; 2015; 116():79-91. PubMed ID: 26377741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis B virus: new therapeutic perspectives.
    Lin CL; Yang HC; Kao JH
    Liver Int; 2016 Jan; 36 Suppl 1():85-92. PubMed ID: 26725903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease.
    Russo FP; Rodríguez-Castro K; Scribano L; Gottardo G; Vanin V; Farinati F
    World J Hepatol; 2015 May; 7(8):1097-104. PubMed ID: 26052398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. cccDNA Maintenance in Chronic Hepatitis B - Targeting the Matrix of Viral Replication.
    Dandri M; Petersen J
    Infect Drug Resist; 2020; 13():3873-3886. PubMed ID: 33149632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA.
    Sheraz M; Cheng J; Tang L; Chang J; Guo JT
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimating hepatitis B virus cccDNA persistence in chronic infection.
    Lythgoe KA; Lumley SF; Pellis L; McKeating JA; Matthews PC
    Virus Evol; 2021 Jan; 7(1):veaa063. PubMed ID: 33732502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
    Dong C; Qu L; Wang H; Wei L; Dong Y; Xiong S
    Antiviral Res; 2015 Jun; 118():110-7. PubMed ID: 25843425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of cccDNA in HBV Maintenance.
    Allweiss L; Dandri M
    Viruses; 2017 Jun; 9(6):. PubMed ID: 28635668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA.
    Ohno M; Otsuka M; Kishikawa T; Yoshikawa T; Takata A; Koike K
    World J Gastroenterol; 2015 Jun; 21(23):7084-8. PubMed ID: 26109795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current and future directions for treating hepatitis B virus infection.
    Tawada A; Kanda T; Yokosuka O
    World J Hepatol; 2015 Jun; 7(11):1541-52. PubMed ID: 26085913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Control and Eradication Strategies of Hepatitis B Virus.
    Shih C; Chou SF; Yang CC; Huang JY; Choijilsuren G; Jhou RS
    Trends Microbiol; 2016 Sep; 24(9):739-749. PubMed ID: 27287929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapamycin inhibits hepatitis B virus covalently closed circular DNA transcription by enhancing the ubiquitination of HBx.
    Zhang Y; Li L; Cheng ST; Qin YP; He X; Li F; Wu DQ; Ren F; Yu HB; Liu J; Chen J; Ren JH; Zhang ZZ
    Front Microbiol; 2022; 13():850087. PubMed ID: 36033851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toward cure chronic hepatitis B infection and hepatocellular carcinoma prevention: Lessons learned from nucleos(t)ide analogues therapy.
    Tavakolpour S; Mirsafaei HS; Elkaei Behjati S; Ghasemiadl M; Akhlaghdoust M; Sali S
    Immunol Lett; 2017 Oct; 190():206-212. PubMed ID: 28827021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B.
    Nassal M
    Gut; 2015 Dec; 64(12):1972-84. PubMed ID: 26048673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Translational Strategies to Eliminate Chronic Hepatitis B in Children: Prophylaxis and Management in East Asian Countries.
    Kang B; Yi DY; Choe BH
    Front Pediatr; 2021; 9():809838. PubMed ID: 35186829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues.
    Rapti I; Hadziyannis S
    World J Hepatol; 2015 May; 7(8):1064-73. PubMed ID: 26052395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma.
    Baran B
    World J Hepatol; 2015 Jul; 7(13):1742-54. PubMed ID: 26167247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of CRISPR/Cas9 Technology to HBV.
    Lin G; Zhang K; Li J
    Int J Mol Sci; 2015 Nov; 16(11):26077-86. PubMed ID: 26540039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.